



**INTERNATIONAL E-CONFERENCE CONTEMPORARY
PHARMACY: ISSUES, CHALLENGES AND EXPECTATIONS**

23rd OF OCTOBER 2020, KAUNAS

ABSTRACT BOOK

2020 autumn

October 23rd, 2020

Kaunas, Lithuania

The international conference “CONTEMPORARY PHARMACY: ISSUES, CHALLENGES AND EXPECTATION. 2020 AUTUMN” is organized by Lithuanian University of Health Sciences, Faculty of Pharmacy, Department of Drug Technology and Social Pharmacy.

Organizing Committee

Chairman

Prof. Dr. Jurga Bernatoniene

Secretaries:

Birutė Juodeikienė

PhD student Inga Matulytė

Members:

Prof. Dr. Ramunė Morkūnienė

Prof. habil. Dr. Arūnas Savickas

Prof. Dr. Nijolė Savickienė

Prof. Dr. Lina Raudonė

Assoc. Prof. Dr. Gailutė Drakšienė

Assoc. Prof. Dr. Vilma Gudienė

Assoc. Prof. Dr. Giedrė Kasparavičienė

Lect. Dr. Agnė Mazurkevičiūtė

Lect. Dr. Gabrielė Balčiūnaitė-Murzienė

PhD student Gabrielė Vilkickytė

PhD student Jurga Andrėja Kazlauskaitė

Scientific Committee

Chairmen

Assoc. Prof. Dr. Giedrė Kasparavičienė

Secretary

PhD student Inga Matulytė

Members from Lithuania:

Prof. Dr. Lina Raudonė

Assoc. Prof. Dr. Daiva Kazlauskienė

Assoc. Prof. Dr. Vilma Gudienė

Lect. Dr. Agnė Mazurkevičiūtė

Lect. Dr. Gabrielė Balčiūnaitė-Murzienė

Lect. Dr. Mindaugas Liaudanskas

Lect. Dr. Vaida Kurapkienė

PhD student Gabrielė Vilkickytė

PhD student Jurga Andrėja Kazlauskaitė

Member from foreign:

Assoc. Prof. Dr. Lesia Savchenko

ISBN 978-9955-15-669-7

2020, Kaunas

Language of abstracts was not corrected.

Digoxin potentiates the anticonvulsant effect of antiepileptic drugs against experimental seizures in mice

Vadim Tsyvunin^{1*}, Sergiy Shtrygol¹, Diana Shtrygol², Mariia Mishchenko¹, Ihor Kapelka¹

¹ Department of Pharmacology and Pharmacotherapy, National University of Pharmacy, Kharkiv, Ukraine

² Department of Clinical Neurology, Psychiatry, and Narcology, School of Medicine, V.

N. Karazin Kharkiv National University, Kharkiv, Ukraine

*Corresponding author's e-mail: tsyvunin-vad@ukr.net

Introduction: The great amount of epilepsy patients in the world with a large percentage of multidrug-resistant forms [1] determine the urgency of developing new approaches to treatment. From separate early studies [2, 3], there is evidence of a pronounced anticonvulsant effect of cardiac glycoside digoxin. However, the influence of digoxin on anticonvulsant effect of classical antiepileptic drugs (AEDs) remain unknown. The aim of the study is investigating the influence of low doses of digoxin on the anticonvulsant effect of the most widely used AEDs – carbamazepine, lamotrigine, sodium valproate, topiramate, levetiracetam, phenobarbital and clonazepam.

Materials and methods: The experiments were conducted on male albino mice. Basic models of pentylenetetrazole-induced seizures and maximal electroshock were used [4]. AEDs were administered intragastrically in conditionally effective (ED_{50}) and sub-effective ($1/2 ED_{50}$) doses at 30 min, digoxin – subcutaneously at a dose of 0.8 mg/kg ($1/10 LD_{50}$) at 15 min before seizures induction. Pentylenetetrazole at a dose of 80 mg/kg was administered subcutaneously. The maximal electroshock was reproduced by transmitting an electric current (strength – 50 mA, frequency – 50 Hz) through the corneal electrodes for 0.2 sec.

Results: Co-administration of digoxin with AEDs in sub-effective doses render a marked anticonvulsant activity on the model of pentylenetetrazole-induced seizures. In addition, digoxin potentiates the effects of all AEDs against convulsions induced by maximal electroshock, providing a distinct protective effect of anticonvulsant medicines in sub-effective doses. It should be mentioned that the pronounced anticonvulsant effect of the combinations “digoxin + AED” is detected even if the mechanism of action of the corresponding AED does not match the pathogenesis of the seizure model.

Conclusions: Digoxin can be a perspective component of complex therapy of epilepsy (including multidrug-resistant one) as it reduces the doses of the antiepileptic drugs with a corresponding reduction in the risk of side effects without compromising treatment efficacy.

References

1. Kalilani L, Sun X, Pelgrims B, Noack-Rink M, Villanueva V. The epidemiology of drug-resistant epilepsy: A systematic review and meta-analysis. *Epilepsia*. 2018;59(12):2179–2193.
2. Markova I, Mikhailov I, Guzeva V. Digoksin – aktivnoe protivoepilepticheskoe sredstvo [Digoxin – an active antiepileptic agent]. *Farmakologiya i toksikologiya – Pharmacology and toxicology*. 1991;(54)5:52–54. [in Russian]
3. Shtrygol' S, & Shtrygol' D. Digoksin kak protivoepilepticheskoe sredstvo u detei (kliniko-eksperimental'noe issledovanie) [Digoxin as an antiepileptic in children (clinical and experimental study)]. *Ukrayinskyi medychnyi al'manakh – Ukrainian Medical Almanac*. 2010;13(4):164. [in Russian]
4. Mironov A, Bunyatyan N, Vasileva A (Eds.). *Rukovodstvo po provedeniyu doklinicheskikh issledovaniy lekarstvennykh sredstv. Ch. 1 [Guidelines for conducting pre-clinical trials of medicines. Part one]*. 2012. Moscow: Grif and K. [in Russian]